Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

ROME, Feb 4 (Reuters) - Italy's economy is ‌estimated to grow by 0.7% both this ‌year and next, the parliamentary budget watchdog UPB said on Wednesday, upgrading its 2026 estimate and slightly ...

Fintel reports that on December 18, 2025, Mizuho initiated coverage of Upstream Bio (NasdaqGS:UPB) with a Outperform recommendation. Analyst Price Forecast Suggests 80.02% Upside As of December 6, ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring ...

Shares of inflammatory disease biotech Upstream Bio, Inc. (UPB) have rallied by roughly 60% since reporting potentially best-in-class data for its asset verekitug in a Phase 2 trial in early September ...

) has been revised to $51.00 / share. This is a decrease of 18.03% from the prior estimate of $62.22 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since ...

The latest price target for Upstream Bio (NASDAQ:UPB) was reported by Evercore ISI Group on November 18, 2025. The analyst firm set a price target for $40.00 expecting UPB to rise to within 12 months ...

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical ...